Compare

Perrigo/$PRGO

1D1W1M3M6MYTD1Y5YMAX

About Perrigo

Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Ticker
$PRGO
Sector
Health
Primary listing
NYSE
Employees
8,100
Headquarters
Dublin, Ireland

Perrigo Metrics

BasicAdvanced
$2.4B
-
-$12.72
0.69
$1.16
6.85%

What the Analysts think about Perrigo

Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Analyst projections of the future price of Perrigo stock.

Bulls say / Bears say

Perrigo gained 30 basis points of US store-brand OTC share in the quarter, while its key European brands grew value sales by 6.5% and gained 80 basis points. That suggests the company is winning customers even in a soft market. (Perrigo)
Core sales declines eased from 8.3% in the first quarter to 1.7% in the third, while adjusted operating margin rose from 12.8% to 14.3%. If this operational improvement continues, it could help restore earnings momentum. (The Motley Fool)
The agreed Infant Formula sale would focus Perrigo on consumer self-care and is expected to improve margins and reduce future capital spending. The deal offers up to $175 million, although only $40 million is upfront and the remainder depends on future milestones. (Perrigo)
Management updated its 2026 outlook to reflect cautious retailer inventory positioning ahead of cough-and-cold season and ongoing weakness in Europe. Those pressures point to uncertain demand and could keep sales under strain. (Perrigo)
Core adjusted gross margin fell 140 basis points to 37.9%, and adjusted EPS dropped 9% year on year to $0.61. Lower volumes and an unfavourable sales mix are weighing on profitability. (Perrigo)
Perrigo had $3.3 billion of debt against $437 million of cash at quarter-end, and management expects year-end net leverage of about four times adjusted EBITDA. That leaves the company with limited financial flexibility if its recovery stalls. (Perrigo)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.

Perrigo Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Perrigo Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.